Methods and compositions for treating melanoma
US-2024424002-A1 · Dec 26, 2024 · US
Methods of prevention or treatment for pathologic thrombosis or inflammation
US9750757B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9750757-B2 |
| Application number | US-201415032790-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 27, 2014 |
| Priority date | Oct 29, 2013 |
| Publication date | Sep 5, 2017 |
| Grant date | Sep 5, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure relates to methods of affecting platelet activation by the use of a PC-TP inhibitor. The PC-TP inhibitor can be administered to a subject in need thereof in order to prevent or treat pathologic thrombosis, or to treat a disorder treatable by a PAR4 inhibitor.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of inhibiting platelet activation, the method comprising contacting a platelet with a PC-TP inhibitor 2,4-dichloro-N-(4-(N-(4,6-dimethylpyrimidin-2-yl)sulfamoyl)phenylcarbamoyl)-benzamide (LDN-193,188), or a pharmaceutically acceptable salt thereof, and wherein the PC-TP inhibitor inhibits PAR4 activation. 2. The method of claim 1 , wherein said contacting is in vitro. 3. The method of claim 1 , wherein said contacting is in vivo. 4. The method of claim 3 , wherein said in vivo contacting is in a subject in need of prevention or treatment for pathologic thrombosis, or treatment for a disorder treatable by a PAR4 inhibitor. 5. The method of claim 4 , wherein said subject is a mammal. 6. The method of claim 5 , wherein said mammal is a human.
Assignees
Inventors
Classifications
having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495}) · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Non condensed pyridines; Hydrogenated derivatives thereof · CPC title
- A61K31/635Primary
having a heterocyclic ring, e.g. sulfadiazine · CPC title
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9750757B2 cover?
- The present disclosure relates to methods of affecting platelet activation by the use of a PC-TP inhibitor. The PC-TP inhibitor can be administered to a subject in need thereof in order to prevent or treat pathologic thrombosis, or to treat a disorder treatable by a PAR4 inhibitor.
- Who is the assignee on this patent?
- Univ Jefferson
- What technology area does this patent fall under?
- Primary CPC classification A61K31/635. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 05 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).